Lee-Jen Wei, PhD

Lee-Jen Wei, PhD

Researcher

Contact Information

Office Phone Number

(617) 432-2826

Fax

(617) 432-5619

Biography

Lee-Jen Wei, PhD

Dr. Wei received his PhD in statistics from the University of Wisconsin-Madison in 1975. Since then, he has held academic appointments at the University of South Carolina, George Washington University, University of Michigan, University of Wisconsin, and Harvard University. He has also worked at the National Cancer Institute, and served as associate editor for the Journal of the American Statistical Association, Biometrics, and Communications in Statistics. Currently, he is director of the Bioinformatics Core of the Harvard School of Public Health.

Researcher

Physician

Professor of Biostatistics, Harvard T.H. Chan School of Public Health

Recent Awards

  • Distinguished Alumni Award, Fu Jen University 1999
  • Greenberg Distinguished Lectureship, University of North Carolina, Chapel Hill 2001

Research

    Developing Quantitative Methods for Designing, Monitoring, and Analyzing Clinical Studies

    Our research focuses on developing statistical methods for the design and analysis of clinical trials. In the late 1970s, Dr. Wei introduced the "urn design" for two-arm sequential clinical studies, a design that has since been used in several large-scale multicenter trials. Later he proposed a response adaptive design, currently utilized in several trials sponsored by private industry, to ameliorate problems arising from the conventional rule of 50-50 randomization treatment allocation in clinical studies. In the 1980s, he presented a monitoring scheme for the interim analysis for clinical trial data.We have also developed numerous methods for analyzing data with multiple outcomes or repeated measurements from study subjects, in particular, "multivariate Cox procedures" for handling multiple event times, as well as alternatives to the Cox proportional hazards model for analyzing survival observations.A critical issue in statistical inference is ascertaining whether the model used for the data is appropriate. Currently, we are developing graphical and numerical methods for checking the adequacy of the Cox proportional hazards model, other semi-parametric survival models, parametric models, and random effects models for repeated measurements. The new procedures are much less subjective than conventional methods based on ordinary residuals plots.Since the cost of computing has dropped, some intractable statistical problems can now be handled numerically. Presently, we are working on various resampling methods for quantile regression, rank regression, and regression models for censored data.

    Publications

      • Efficacy, Safety, and Analysis Issues in a Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer. JAMA Surg. 2023 Aug 16. View in: Pubmed

      • Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2023 Aug 03; JCO2300288. View in: Pubmed

      • Chronic Pain and Pain Management in Older Adults: Protocol and Pilot Results. Nurs Res. 2023 Jul 31. View in: Pubmed

      • Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML. J Clin Oncol. 2023 09 20; 41(27):4446-4447. View in: Pubmed

      • Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. JAMA Cardiol. 2023 06 01; 8(6):554-563. View in: Pubmed

      • Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies. JAMA Netw Open. 2023 06 01; 6(6):e2319055. View in: Pubmed

      • Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event-Moving Beyond C Statistic: A Review. JAMA Cardiol. 2023 03 01; 8(3):290-295. View in: Pubmed

      • Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer. J Clin Oncol. 2023 04 01; 41(10):1952-1953. View in: Pubmed

      • Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma. JAMA. 2023 Jan 17; 329(3):261. View in: Pubmed

      • Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. J Clin Oncol. 2023 02 20; 41(6):1323. View in: Pubmed

      • Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. JAMA Oncol. 2022 11 01; 8(11):1701. View in: Pubmed

      • Pembrolizumab in Triple-Negative Breast Cancer. N Engl J Med. 2022 10 13; 387(15):1435. View in: Pubmed

      • Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial. JAMA Oncol. 2022 10 01; 8(10):1502-1503. View in: Pubmed

      • Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 12 20; 40(36):4278-4279. View in: Pubmed

      • Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial. J Gen Intern Med. 2022 Nov; 37(15):3797-3804. View in: Pubmed

      • Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. NEJM Evid. 2022 Oct; 1(10). View in: Pubmed

      • Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years. JAMA Oncol. 2022 06 01; 8(6):1. View in: Pubmed

      • Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. JAMA Surg. 2022 05 01; 157(5):458-459. View in: Pubmed

      • Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review. JAMA Cardiol. 2022 04 01; 7(4):450-456. View in: Pubmed

      • Questions About a Risk Prediction Model of Mortality After Esophagectomy for Cancer. JAMA Surg. 2022 03 01; 157(3):279-280. View in: Pubmed

      • Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations. JNCI Cancer Spectr. 2022 01 05; 6(1). View in: Pubmed

      • Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer. JAMA Oncol. 2022 01 01; 8(1):167-168. View in: Pubmed

      • Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Stat Med. 2021 12 10; 40(28):6235-6242. View in: Pubmed

      • Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. J Immunother Cancer. 2021 11; 9(11). View in: Pubmed

      • Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population. JAMA Oncol. 2021 11 01; 7(11):1723-1724. View in: Pubmed

      • Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open. 2021 09 13; 11(9):e050335. View in: Pubmed

      • Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment. Muscle Nerve. 2021 11; 64(5):614-619. View in: Pubmed

      • Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies. Clin Infect Dis. 2021 06 01; 72(11):e887-e889. View in: Pubmed

      • Restricted mean survival time versus conventional measures for treatment decision-making. J Am Geriatr Soc. 2021 08; 69(8):2282-2289. View in: Pubmed

      • Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients. JAMA. 2021 04 20; 325(15):1566-1567. View in: Pubmed

      • Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer. JAMA Oncol. 2021 04 01; 7(4):632-633. View in: Pubmed

      • Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 03 25; 384(12):1174. View in: Pubmed

      • Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis for Low Rectal Cancers. JAMA Surg. 2021 02 01; 156(2):202-203. View in: Pubmed

      • Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia. JAMA Netw Open. 2021 01 04; 4(1):e2034745. View in: Pubmed

      • Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". Circulation. 2021 01 05; 143(1):e1-e2. View in: Pubmed

      • Appropriate Analysis of Duration of Response Data in Cancer Trials. JAMA Oncol. 2020 12 01; 6(12):1978. View in: Pubmed

      • Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. EJHaem. 2021 Feb; 2(1):48-55. View in: Pubmed

      • Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2021 01; 79(1):e10-e11. View in: Pubmed

      • Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. JACC Heart Fail. 2020 12; 8(12):973-983. View in: Pubmed

      • Progression-free survival in the ICON8 trial. Lancet. 2020 09 12; 396(10253):756. View in: Pubmed

      • Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. Contemp Clin Trials. 2020 10; 97:106145. View in: Pubmed

      • Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2020 10; 9(14):973-984. View in: Pubmed

      • Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet. 2020 08 08; 396(10248):378-379. View in: Pubmed

      • Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. JAMA Oncol. 2020 08 01; 6(8):1301-1302. View in: Pubmed

      • Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 09 03; 383(10):993. View in: Pubmed

      • Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Ann Intern Med. 2020 09 01; 173(5):368-374. View in: Pubmed

      • How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Ann Intern Med. 2020 10 20; 173(8):632-637. View in: Pubmed

      • Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Oncol. 2020 07 01; 6(7):1121-1122. View in: Pubmed

      • Fulvestrant plus capivasertib for metastatic breast cancer. Lancet Oncol. 2020 05; 21(5):e233. View in: Pubmed

      • Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value. J Clin Oncol. 2020 06 10; 38(17):2001-2002. View in: Pubmed

      • Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy. JAMA Netw Open. 2020 02 05; 3(2):e1921306. View in: Pubmed

      • Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older. JAMA Cardiol. 2020 02 01; 5(2):235. View in: Pubmed

      • Using Confidence Intervals to Quantify Statistical and Clinical Evidence for the Treatment Effect in a Comparative Study-Moving Beyond P Values. JAMA Otolaryngol Head Neck Surg. 2020 01 01; 146(1):5-6. View in: Pubmed

      • Quantifying the benefit of non-small-cell lung cancer immunotherapy. Lancet. 2019 11 23; 394(10212):1904. View in: Pubmed

      • P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JAMA. 2019 10 22; 322(16):1607. View in: Pubmed

      • Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. Circulation. 2019 10 22; 140(17):1366-1368. View in: Pubmed

      • A Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 09 12; 381(11):e22. View in: Pubmed

      • Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz058. View in: Pubmed

      • Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)". Ann Surg. 2019 08; 270(2):e48-e50. View in: Pubmed

      • Analysis of Long-term Benefits of Intensive Blood Pressure Control. JAMA. 2019 07 09; 322(2):169-170. View in: Pubmed

      • Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. Am Heart J. 2019 09; 215:178-186. View in: Pubmed

      • Biodegradable-polymer stents versus durable-polymer stents. Lancet. 2019 05 11; 393(10184):1932-1933. View in: Pubmed

      • Effects of Aspirin in the Healthy Elderly. N Engl J Med. 2019 05 02; 380(18):1775-1776. View in: Pubmed

      • Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circ Cardiovasc Qual Outcomes. 2019 05; 12(5):e005095. View in: Pubmed

      • Quantifying the Treatment Effect of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy. JAMA Cardiol. 2019 05 01; 4(5):494. View in: Pubmed

      • Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. JAMA Surg. 2019 05 01; 154(5):466-467. View in: Pubmed

      • Interpreting the Prognostic Value of Unrecognized Myocardial Infarction Among Older Adults. JAMA Cardiol. 2019 04 01; 4(4):391. View in: Pubmed

      • Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus. J Clin Oncol. 2019 04 20; 37(12):1032-1033. View in: Pubmed

      • Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates. JAMA Cardiol. 2019 03 01; 4(3):299. View in: Pubmed

      • Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective. JAMA Surg. 2019 03 01; 154(3):270-271. View in: Pubmed

      • Palbociclib and Fulvestrant in Breast Cancer. N Engl J Med. 2019 02 21; 380(8):796. View in: Pubmed

      • Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer. JAMA Oncol. 2019 02 01; 5(2):270. View in: Pubmed

      • Trifluridine/tipiracil in metastatic gastric cancer. Lancet Oncol. 2019 01; 20(1):e8. View in: Pubmed

      • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease. J Alzheimers Dis. 2019; 67(2):555-570. View in: Pubmed

      • Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JAMA Oncol. 2019 01 01; 5(1):117-118. View in: Pubmed

      • Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma. JAMA Oncol. 2019 01 01; 5(1):112-113. View in: Pubmed

      • Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2019 01 01; 5(1):114-115. View in: Pubmed

      • Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma. JAMA Surg. 2019 01 01; 154(1):96. View in: Pubmed

      • Quantifying Immunoscore performance. Lancet. 2018 11 03; 392(10158):1624. View in: Pubmed

      • Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. JAMA Oncol. 2018 11 01; 4(11):1617-1618. View in: Pubmed

      • Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer. N Engl J Med. 2018 Oct 25; 379(17):1681. View in: Pubmed

      • Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. J Am Geriatr Soc. 2018 10; 66(10):1987-1991. View in: Pubmed

      • Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018 09 13; 379(11):e18. View in: Pubmed

      • Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018 08; 19(8):e377. View in: Pubmed

      • Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time. Am J Med. 2019 01; 132(1):13-15. View in: Pubmed

      • Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncol. 2018 08 01; 4(8):1135-1136. View in: Pubmed

      • Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. JAMA Oncol. 2018 08 01; 4(8):1137-1138. View in: Pubmed

      • Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. Stat Med. 2018 11 10; 37(25):3589-3598. View in: Pubmed

      • Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. JAMA Oncol. 2018 06 01; 4(6):881-882. View in: Pubmed

      • Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study. JAMA Oncol. 2018 06 01; 4(6):874-876. View in: Pubmed

      • Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. Ann Oncol. 2018 05 01; 29(5):1092-1094. View in: Pubmed

      • Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors. JAMA Oncol. 2018 05 01; 4(5):743. View in: Pubmed

      • Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. JAMA Oncol. 2018 04 01; 4(4):585. View in: Pubmed

      • Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. JAMA Cardiol. 2018 04 01; 3(4):357-358. View in: Pubmed

      • Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. J Clin Oncol. 2018 05 01; 36(13):1378-1379. View in: Pubmed

      • Defining Study Outcomes That Better Reflect Individual Response to Treatment. Pediatr Infect Dis J. 2018 03; 37(3):258-262. View in: Pubmed

      • Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. J Clin Oncol. 2018 03 10; 36(8):825-826. View in: Pubmed

      • Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. J Clin Oncol. 2018 03 01; 36(7):720-721. View in: Pubmed

      • Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306. View in: Pubmed

      • Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncol. 2017 12 01; 3(12):1692-1696. View in: Pubmed

      • Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. JAMA Cardiol. 2017 11 01; 2(11):1179-1180. View in: Pubmed

      • Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. JAMA Oncol. 2017 10 01; 3(10):1430-1431. View in: Pubmed

      • Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. Biometrics. 2018 06; 74(2):694-702. View in: Pubmed

      • Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. J Clin Oncol. 2017 10 10; 35(29):3373. View in: Pubmed

      • How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy? J Clin Oncol. 2016 11 01; 34(31):3818. View in: Pubmed

      • Safety Study of Salmeterol in Asthma in Adults. N Engl J Med. 2016 09 15; 375(11):1097. View in: Pubmed

      • Neratinib after trastuzumab in patients with HER2-positive breast cancer. Lancet Oncol. 2016 05; 17(5):e176. View in: Pubmed

      • Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2016 02 04; 374(5):492-3. View in: Pubmed

      • A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. Biometrics. 2016 09; 72(3):877-87. View in: Pubmed

      • Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015 Jul 21; 163(2):127-34. View in: Pubmed

      • Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):772-9.e1-3. View in: Pubmed

      • Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Biostatistics. 2015 Jan; 16(1):60-72. View in: Pubmed

      • Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014 Aug 01; 32(22):2380-5. View in: Pubmed

      • Effects of bracing in adolescents with idiopathic scoliosis. N Engl J Med. 2014 02 13; 370(7):680. View in: Pubmed

      • Moving beyond our comfort zone. Eur Heart J. 2013 Mar; 34(12):869-71. View in: Pubmed

      • Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials. 2012 Oct; 9(5):570-7. View in: Pubmed

      • On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial. Biostatistics. 2012 Apr; 13(2):256-73. View in: Pubmed

      • Analytical issues regarding rosiglitazone meta-analysis. Arch Intern Med. 2011 Jan 24; 171(2):179-80; author reply 180. View in: Pubmed

      • The highest confidence density region and its usage for joint inferences about constrained parameters. Biometrics. 2011 Jun; 67(2):604-10. View in: Pubmed

      • Estimating subject-specific dependent competing risk profile with censored event time observations. Biometrics. 2011 Jun; 67(2):427-35. View in: Pubmed

      • Pooled association tests for rare variants in exon-resequencing studies. Am J Hum Genet. 2010 Jun 11; 86(6):832-8. View in: Pubmed

      • Impact of acute serum creatinine elevation in patients treated with nesiritide. Clin Cardiol. 2009 Apr; 32(4):215-9. View in: Pubmed

      • Combining association tests across multiple genetic markers in case-control studies. Hum Hered. 2008; 65(3):166-74. View in: Pubmed

      • Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig. 2007; 27(1):35-49. View in: Pubmed

      • Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. Obesity (Silver Spring). 2006 Nov; 14(11):2089-98. View in: Pubmed

      • Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol. 2006 Jul; 195(1):162-71. View in: Pubmed

      • Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis. 2005 Jan 01; 40(1):136-45. View in: Pubmed

      • Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004 Jul 01; 36(3):772-6. View in: Pubmed

      • dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004 May 22; 20(8):1233-40. View in: Pubmed

      • Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004 Jan 01; 64(1):64-71. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 232 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 232 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Discovery and Insights